应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
PVLA Palvella Therapeutics
交易中 05-02 12:37:14 EDT
23.58
-0.51
-2.12%
最高
24.83
最低
23.55
成交量
1.71万
今开
24.24
昨收
24.09
日振幅
5.33%
总市值
2.60亿
流通市值
1.48亿
总股本
1,102万
成交额
41.09万
换手率
0.27%
流通股本
629.23万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。
金融界 · 02-05
Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。
公司概况
公司名称：
Palvella Therapeutics
所属市场：
NASDAQ
上市日期：
2015-06-30
主营业务：
Palvella Therapeutics, Inc.在内华达的法律下成立于2013年5月24日。该公司是一家生物技术公司，历史上发现并开发了基于Anticalin蛋白的药物，以独特和变革性的方式靶向已验证的疾病途径。2024年3月27日，公司实施了措施，以最大限度地提高其从其合作候选药物临床管道收集潜在里程碑的能力，并保持其考虑其他战略选择的能力。该公司的临床管线包括与合作者合作的免疫肿瘤学或IO双特异性药物，包括靶向PD-L1和4-1BB的S095012（也称PRS-344）、靶向CD228和4-1BB的SGN-BB228（也称PRS-346）以及靶向GPC3和4-1BB的BOS-342（也称PRS-342）。Anticalin蛋白是公司专有的，是一类新型疗法，已在临床上通过与领先制药公司的合作关系得到验证。
发行价格：
2.75
{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":23.58,"timestamp":1746203825006,"preClose":24.09,"halted":0,"volume":17089,"delay":0,"floatShares":6292255,"shares":11018747,"eps":-7.832217,"marketStatus":"交易中","change":-0.51,"latestTime":"05-02 12:37:14 EDT","open":24.24,"high":24.83,"low":23.545,"amount":410868.007315,"amplitude":0.053342,"askPrice":24.15,"askSize":100,"bidPrice":23.55,"bidSize":133,"shortable":3,"etf":0,"ttmEps":-7.832217,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1746216000000},"marketStatusCode":2,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":24.09,"preHourTrading":{"tag":"盘前","latestPrice":23.95,"preClose":24.09,"latestTime":"05:44 EDT","volume":125,"amount":2908.21,"timestamp":1746179077826},"postHourTrading":{"tag":"盘后","latestPrice":23.97,"preClose":24.09,"latestTime":"16:21 EDT","volume":261,"amount":6263.4,"timestamp":1746130901226},"volumeRatio":0.337658,"impliedVol":0.3947,"impliedVolPercentile":0.5152},"requestUrl":"/m/hq/s/PVLA/wiki","defaultTab":"wiki","newsList":[{"id":"2509407655","title":"Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407655","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509407655?lang=zh_cn&edition=full","pubTime":"2025-02-05 20:11","pubTimestamp":1738757515,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05201147968471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","PVLA","TD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":-0.0542},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.8531},{"period":"6month","weight":0.3925},{"period":"1year","weight":1.0625},{"period":"ytd","weight":1.0075}],"compareEarnings":[{"period":"1week","weight":0.0215},{"period":"1month","weight":-0.0045},{"period":"3month","weight":-0.072},{"period":"6month","weight":-0.022},{"period":"1year","weight":0.1162},{"period":"ytd","weight":-0.0471}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Palvella Therapeutics, Inc.在内华达的法律下成立于2013年5月24日。该公司是一家生物技术公司，历史上发现并开发了基于Anticalin蛋白的药物，以独特和变革性的方式靶向已验证的疾病途径。2024年3月27日，公司实施了措施，以最大限度地提高其从其合作候选药物临床管道收集潜在里程碑的能力，并保持其考虑其他战略选择的能力。该公司的临床管线包括与合作者合作的免疫肿瘤学或IO双特异性药物，包括靶向PD-L1和4-1BB的S095012（也称PRS-344）、靶向CD228和4-1BB的SGN-BB228（也称PRS-346）以及靶向GPC3和4-1BB的BOS-342（也称PRS-342）。Anticalin蛋白是公司专有的，是一类新型疗法，已在临床上通过与领先制药公司的合作关系得到验证。","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.102904},{"month":2,"riseRate":0.5,"avgChangeRate":0.02179},{"month":3,"riseRate":0.5,"avgChangeRate":0.012293},{"month":4,"riseRate":0.2,"avgChangeRate":-0.082116},{"month":5,"riseRate":0.5,"avgChangeRate":0.168047},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.091514},{"month":7,"riseRate":0.7,"avgChangeRate":0.124373},{"month":8,"riseRate":0.6,"avgChangeRate":0.081761},{"month":9,"riseRate":0.3,"avgChangeRate":-0.115283},{"month":10,"riseRate":0.2,"avgChangeRate":-0.082714},{"month":11,"riseRate":0.5,"avgChangeRate":0.04477},{"month":12,"riseRate":0.3,"avgChangeRate":-0.058257}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Palvella Therapeutics(PVLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Palvella Therapeutics(PVLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}